Literature DB >> 17991951

NICE on dementia: Omitting donepezil is hardly a hardship.

Thomas E Finucane.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17991951      PMCID: PMC2072019          DOI: 10.1136/bmj.39388.433137.1F

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  2 in total

1.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Authors:  C Courtney; D Farrell; R Gray; R Hills; L Lynch; E Sellwood; S Edwards; W Hardyman; J Raftery; P Crome; C Lendon; H Shaw; P Bentham
Journal:  Lancet       Date:  2004-06-26       Impact factor: 79.321

2.  Donepezil for the treatment of agitation in Alzheimer's disease.

Authors:  Robert J Howard; Edmund Juszczak; Clive G Ballard; Peter Bentham; Richard G Brown; Roger Bullock; Alistair S Burns; Clive Holmes; Robin Jacoby; Tony Johnson; Martin Knapp; James Lindesay; John T O'Brien; Gordon Wilcock; Cornelius Katona; Roy W Jones; Julia DeCesare; Michaela Rodger
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

  2 in total
  1 in total

1.  The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis.

Authors:  Lewis O J Killin; Tom C Russ; John M Starr; Sharon Abrahams; Sergio Della Sala
Journal:  BMJ Open       Date:  2014-04-07       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.